AMGN · Full Picture

AMGEN INC — the full picture

Earnings window · 2026-07-15 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Operating Cash Flow Trends · Cash flow generationPriority 83
    +17.6% cash (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Operating cash flow was $4.0 billion in Q2 ’26 versus $2.3 billion in Q2 ’25, an increase of $1.7 billion.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 82
    +30.8% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
    UPLIZNA sales increased 90% year-over-year to $335 million in the second quarter, primarily driven by volume growth.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 79
    -125.1% operating_income; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Total estimated future amortization of finite-lived intangible assets remaining: six months ending Dec 31, 2026 $1.8 billion; 2027 $3.6 billion; 2028 $2.8 billion; 2029 $2.3 billion; 2030 $2.2 billion; 2031 $2.1 billion
  4. Operating Income and Margins · Operating income & profitabilityPriority 76
    +31.9% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    For the second quarter, GAAP operating income increased from $2.7 billion to $3.5 billion.
  5. Guidance and Outlook · Guidance & outlookPriority 72
    3 sources (news, press_release, sec_filing); 12 forward row(s); quote_verified
    For the full year 2026, the Company expects Total revenues in the range of $38.2 billion to $39.4 billion.
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 70
    -9.5% liability (realized); 1 forward row(s); structured_verified
    During the six months ended June 30, 2026, we repaid the €750 million aggregate principal amount of our 2.00% 2026 euro Notes ($833 million upon settlement of the related cross-currency swap), compared to $3.5 billion of debt repayments during the six months ended June 30, 2025.
  7. Competition and Pricing Pressure · Competition & market sharePriority 64
    -3.8% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Prolia sales decreased 32% year-over-year to $759 million in the second quarter, driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected.
  8. Capital Expenditure Outlook · UnclassifiedPriority 62
    2 forward row(s); quote_verified
    For the full year 2026, capital expenditures are expected to be approximately $2.6 billion.
  9. Capital Expenditures Program · Capital expenditurePriority 62
    -2.3% cash; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Cash used in investing activities during the six months ended June 30, 2026 and 2025 was primarily due to capital expenditures of $1.2 billion and $780 million, respectively, including construction costs for new plants and expansion of manufacturing capacity.
  10. Capital Return Program · Buybacks & dividendsPriority 60
    1 forward row(s); quote_verified
    For the full year 2026, share repurchases are not to exceed $3.0 billion.
  11. Quarterly Dividend Declaration · Buybacks & dividendsPriority 60
    2 sources (news, sec_filing); 1 forward row(s); quote_verified
    In July 2026, our Board of Directors declared a quarterly cash dividend of $2.52 per share of common stock to be paid in September 2026.
  12. Reimbursement and Payer Mix · Compliance & policy costsPriority 59
    1 forward row(s); quote_verified
    In January 2025 Otezla was selected by CMS for Medicare price setting applicable beginning January 1, 2027

Threads by pillar

Revenue & Demand Priority 92 · 5 threads

Costs & Margins Priority 86 · 4 threads

Capital & Balance Sheet Priority 94 · 7 threads

Legal, Regulatory & Policy Priority 75 · 6 threads

Guidance & Outlook Priority 72 · 1 thread

Macro & Market Conditions Priority 67 · 2 threads

Management & Governance Priority 32 · 1 thread

Unclassified Priority 74 · 4 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-125.1%+125.1%+44.9%
cash-2.3%+2.3%+20.3%
assets+2.3%+2.3%+6.5%
liability-1.3%+1.6%-9.5%
margin——+20.4%
net_income——+10.3%
revenue——+27.1%